Dermatological Considerations for Transgender and Gender Diverse Patients: An Australian Perspective

The document discusses dermatological considerations for transgender and gender diverse (TGD) patients in Australia, emphasizing the importance of supportive, knowledgeable, and multidisciplinary care. It highlights the effects of gender-affirming hormone (GAH) therapy, such as increased facial and body hair growth, acne, and androgenetic alopecia (AGA) in masculinizing therapy, and reduced hair growth and softened skin in feminizing therapy. Treatments like minoxidil, finasteride, and spironolactone are discussed for managing AGA and acne. The document also covers the necessity of permanent hair removal for gender-affirming surgeries, the use of neurotoxins and fillers for facial restructuring, and the higher risk of HIV and other dermatoses in TGD populations. It underscores the need for dermatologists to use preferred names and pronouns, understand the unique needs of TGD individuals, and collaborate with other healthcare providers to improve health outcomes.